Effect of Denosumab or Alendronate on Vascular Calcification: Secondary Analysis of SALTIRE2 Randomized Controlled Trial
Journal of the American Heart Association · 2024
DOI: 10.1161/jaha.123.032571 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Jolien Geers und 20 weiteren Autor:innen. Beteiligte Einrichtung: BHF Centre for Cardiovascular Science University of Edinburgh Edinburgh UK. Hauptthemen laut MEDLINE: Denosumab, Vascular Calcification, Alendronate, Bone Density Conservation Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, British Heart Foundation.
Abstract (Originalsprache)
Background
Patients with osteoporosis demonstrate increased vascular calcification but the effect of osteoporosis treatments on vascular calcification remains unclear. The present study aimed to examine whether coronary or aortic calcification are influenced by denosumab and alendronic acid treatment. Methods and Results In a double‐blind randomized controlled SALTIRE2 (Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis) trial, patients with aortic stenosis were randomized 2:1:2:1 to denosumab, placebo injection, alendronic acid, or placebo capsule. Participants underwent serial imaging with computed tomography and 18F‐sodium fluoride positron emission tomography for the assessment of vascular calcium burden and calcification activity, respectively. We report the prespecified secondary analyses of 24‐month change in coronary calcium score, and 12‐month changes in thoracic aorta calcium score, coronary and aortic 18F‐sodium fluoride activity. One hundred fifty patients with aortic stenosis (72±8 years; 21% female) were randomized to denosumab (n=49), alendronic acid (n=51), and placebo (injection n=25, capsule n=25). There were no differences in change in coronary calcium scores between placebo (16 [−64 to 148] Agatston units) and either denosumab (94 [0–212] Agatston units, P =0.24) or alendronic acid (34 [−62 to 134], P =0.99). There were no differences in change in thoracic aorta calcium scores between placebo (132 [22–512] Agatston units) and either denosumab (118 [11–340], P =0.75) or alendronic acid (116 [26–498] Agatston units, P =0.62). There were no differences in changes in coronary or aortic 18F‐sodium fluoride activity between treatment groups.
Conclusions
Neither alendronic acid nor denosumab are associated with changes in the activity or progression of coronary or aortic calcification. Osteoporosis treatments do not appear to have major impact on vascular calcification of atherosclerosis. registration https://www.clinicaltrials.gov ; Unique identifier: NCT02132026.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BHF Centre for Cardiovascular Science University of Edinburgh Edinburgh UK.
- Department of Cardiology Universitair Ziekenhuis Brussel (UZ Brussel) Vrije Universiteit Brussel (VUB) Brussels Belgium.
- Department of Child Health University of Glasgow Glasgow UK.
- Edinburgh Clinical Trials Unit University of Edinburgh Edinburgh UK.
- Edinburgh Clinical Research Facility University of Edinburgh Edinburgh UK.
- Department of Interventional Cardiology and Angiology Institute of Cardiology Warsaw Poland.
ORCID-Profile: Jolien Geers, Rong Bing, Alexander J Fletcher, Audrey C White, Laura Forsyth, Jacek Kwieciński, Michelle C Williams, Edwin J R van Beek, Soongu Kwak, Evangelos Tzolos, Piotr J Slomka, Christophe Lucatelli, Stuart H Ralston, David E Newby, Marc R Dweck
Förderung
- Wellcome Trust
- British Heart Foundation
Zitieren
APA
Geers, J., Bing, R., Pawade, T. A., Doris, M. K., Daghem, M., Fletcher, A. J., White, A. C., Forsyth, L., Evans, E., Kwieciński, J., Williams, M. C., van Beek, E. J. R., Kwak, S., Peeters, F. E. C. M., Tzolos, E., Slomka, P. J., Lucatelli, C., Ralston, S. H., Prendergast, B., …, & Dweck, M. R. (2024). Effect of Denosumab or Alendronate on Vascular Calcification: Secondary Analysis of SALTIRE2 Randomized Controlled Trial. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.032571
Vancouver
Geers J, Bing R, Pawade TA, Doris MK, Daghem M, Fletcher AJ, et al. Effect of Denosumab or Alendronate on Vascular Calcification: Secondary Analysis of SALTIRE2 Randomized Controlled Trial. Journal of the American Heart Association. 2024. doi:10.1161/jaha.123.032571
BibTeX
@article{Geers2024,
author = {Geers, Jolien and Bing, Rong and Pawade, Tania A and Doris, Mhairi K and Daghem, Marwa and Fletcher, Alexander J and White, Audrey C and Forsyth, Laura and Evans, Emily and Kwieciński, Jacek and Williams, Michelle C and van Beek, Edwin J R and Kwak, Soongu and Peeters, Frederique E C M and Tzolos, Evangelos and Slomka, Piotr J and Lucatelli, Christophe and Ralston, Stuart H and Prendergast, Bernard and Newby, David E and Dweck, Marc R},
title = {Effect of Denosumab or Alendronate on Vascular Calcification: Secondary Analysis of SALTIRE2 Randomized Controlled Trial},
journal = {Journal of the American Heart Association},
year = {2024},
doi = {10.1161/jaha.123.032571}
}
EUVIMED